ChemSpider 2D Image | Dolutegravir | C20H19F2N3O5

Dolutegravir

  • Molecular FormulaC20H19F2N3O5
  • Average mass419.379 Da
  • Monoisotopic mass419.129272 Da
  • ChemSpider ID25051637

  • defined stereocentres - 2 of 2 defined stereocentres

More details:

Featured data source
The Merck Index Online

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(4R,12aS)-N-(2,4-Difluorbenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-9-carboxamid [German] [ACD/IUPAC Name]
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide [ACD/IUPAC Name]
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-méthyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide [French] [ACD/IUPAC Name]
(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
1051375-16-6 [RN]
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)- [ACD/Index Name]
DKO1W9H7M1
Dolutegravir [INN] [USAN] [Wiki]
Dolutegravir [Spanish] [INN]
Dolutégravir [French] [INN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

9261 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Safety:

      J05AX12 Wikidata Q937224

    • Chemical Class:

      A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4<stereo>R</stereo>,12a<stereo>S</stereo>)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2<element>H</eleme nt>-pyrido[1',2':4,5]pyrazino[2,1-<ital>b</ital>][1,3]oxazine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. ChEBI CHEBI:76010
      A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-ca rboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. ChEBI https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:76010

    • Bio Activity:

      Anti-infection MedChem Express HY-13238
      Anti-infection; Metabolism/Protease; MedChem Express HY-13238
      Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. MedChem Express
      Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.; IC50 Value: 2.7 nM; Target: HIV Integrase; Dolutegravir (DTG, GSK1349572) is metabolized primarily by uridine diphosphate glucuronyltransferase (UGT)1A1, with a minor role of cytochrome P450 (CYP)3A, and with renal elimination of unchanged drug being extremely low (< 1% of the dose). MedChem Express HY-13238
      Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.;IC50 Value: 2.7 nM;Target: HIV IntegraseDolutegravir (DTG, GSK1349572) is metabolized primarily by uridine diphosphate glucuronyltransferase (UGT)1A1, with a minor role of cytochrome P450 (CYP)3A, and with renal elimination of unchanged drug being extremely low (< 1% of the dose). Fifty-three percent of the total oral dose is excreted unchanged in the feces but it is unknown if all or part of this is due to unabsorbed drug or some percentage of biliary excretion of the glucuronide conjugate which can be further degraded to form the parent compound in the gut lumen. The current Food and Drug Administration (FDA) draft guidance for renal impairment studies states that a pharmacokinetic (PK) study in patients with renal impairment should be conducted even for those drugs primarily metabolized or secreted in bile, MedChem Express HY-13238
      HIV MedChem Express HY-13238
      HIV HIV Integrase MedChem Express HY-13238

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.5±0.1 g/cm3
Boiling Point: 669.0±55.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.1 mmHg at 25°C
Enthalpy of Vaporization: 103.3±3.0 kJ/mol
Flash Point: 358.4±31.5 °C
Index of Refraction: 1.650
Molar Refractivity: 99.8±0.4 cm3
#H bond acceptors: 8
#H bond donors: 2
#Freely Rotating Bonds: 3
#Rule of 5 Violations: 0
ACD/LogP: -1.32
ACD/LogD (pH 5.5): -1.32
ACD/BCF (pH 5.5): 1.00
ACD/KOC (pH 5.5): 1.80
ACD/LogD (pH 7.4): -3.10
ACD/BCF (pH 7.4): 1.00
ACD/KOC (pH 7.4): 1.00
Polar Surface Area: 99 Å2
Polarizability: 39.6±0.5 10-24cm3
Surface Tension: 67.4±5.0 dyne/cm
Molar Volume: 273.8±5.0 cm3

Click to predict properties on the Chemicalize site


Advertisement